Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study.

ABSTRACT:

Background

Use of bridging anticoagulation increases a patient's bleeding risk without clear evidence of thrombotic prevention among warfarin-treated patients with atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin-treated patients with venous thromboembolism (VTE) has not been studied.

Methods

We identified warfarin-treated patients with VTE who temporarily stopped warfarin for a surgical procedure between 2010 and 2018 at six health systems. Using the 2012 American College of Chest Physicians guideline, we assessed use of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent VTE risk and 30-day outcomes (bleeding, thromboembolism, emergency department visit) were each assessed using logistic regression adjusted for mul

SUBMITTER: Barnes GD 

PROVIDER: S-EPMC7415673 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature